Infection is one of the most consequential complications of a diabetic foot ulcer. Roughly 40% of diabetes-related foot ulcers become infected, and infection is a leading precipitant of hospitalization and lower-extremity amputation (Matheson et al., 2021). Because the clinical signs of infection can be muted in people with neuropathy and impaired circulation, accurate diagnosis, appropriate sampling, and well-judged antibiotic therapy are central to good outcomes. This article reviews what current guidelines and trials show for soft-tissue infection of the diabetic foot.
Diagnosing and Grading Infection
Infection is diagnosed clinically, not by laboratory tests or swab results alone. The IWGDF/IDSA classification requires at least two of the classic signs of inflammation (redness, warmth, swelling or induration, pain or tenderness) or the presence of purulent discharge in a wound (Lipsky et al., 2020; Senneville et al., 2023). Severity then guides the setting and route of treatment:
- Mild (IWGDF grade 2): involves only skin and subcutaneous tissue, with erythema extending less than 2 cm around the wound.
- Moderate (grade 3): erythema of 2 cm or more, or involvement of deeper structures such as fascia, muscle, tendon, or joint, without systemic signs.
- Severe (grade 4): infection accompanied by systemic inflammatory response features such as fever, tachycardia, tachypnea, or abnormal white cell count.
An added “(O)” designation indicates concurrent osteomyelitis, which changes management and is considered separately (Matheson et al., 2021). Perfusion should also be assessed in every infected foot.
Cultures: Quality Over Convenience
Superficial swabs of an open wound frequently grow colonizing organisms that are not the cause of the infection. For this reason, guidelines advise against relying on superficial wound cultures and recommend obtaining specimens only from clinically infected wounds, ideally as deep tissue after cleansing and debridement of the wound (Lipsky et al., 2020; Matheson et al., 2021).
Empiric therapy for mild and many moderate infections generally targets Gram-positive cocci, principally Staphylococcus aureus and streptococci. Broader coverage, including for Gram-negative organisms and anaerobes, is reserved for severe infections, chronic or previously treated wounds, and settings where risk factors are present. A negative nasal screen for methicillin-resistant S. aureus has a high negative predictive value and can support avoiding anti-MRSA agents (Matheson et al., 2021).
How Long Should Antibiotics Continue?
Duration is where stewardship matters most. Evidence consistently shows that longer courses do not improve outcomes for soft-tissue infection. Current IWGDF/IDSA recommendations support a course of one to two weeks for mild-to-moderate skin and soft-tissue infection, with extension to three to four weeks if the infection is slow to resolve or the patient has severe peripheral artery disease. Treatment should be stopped once signs of infection have resolved, even if the wound has not yet healed, since an open wound alone is not an indication for continued antibiotics (Senneville et al., 2023; Matheson et al., 2021). Oral therapy is appropriate for most mild infections, while severe infections require initial intravenous treatment and urgent assessment for surgical drainage.
Trials in diabetic foot osteomyelitis reinforce the principle that shorter courses can be sufficient. In a randomized trial of 40 episodes, Tone and colleagues (2015) found no significant difference in remission between 6 and 12 weeks of antibiotics, with fewer gastrointestinal adverse events in the shorter group (15% versus 45%). Gariani et al. (2021) reported cure in 84% of patients treated for 3 weeks versus 73% treated for 6 weeks. A narrative review by Maurer et al. (2022) concluded that therapy for osteomyelitis should generally not exceed 4 to 6 weeks and may be shorter in selected cases, particularly after resection of infected bone.
Source Control and Perfusion
Antibiotics alone do not resolve abscesses, necrotic tissue, or foreign material. Guidelines emphasize prompt surgical drainage and debridement for deep abscesses, necrotizing infection, and compartment involvement, and urgent specialist referral for moderate-to-severe infection, particularly when limb perfusion is compromised (Senneville et al., 2023). Where significant peripheral artery disease coexists, vascular assessment and consideration of revascularization form part of infection management rather than a separate step.
Key Takeaways
Diabetic foot infection is a clinical diagnosis graded by depth, extent, and systemic involvement. Deep tissue specimens are preferable to superficial swabs, and uninfected wounds should not be treated with antibiotics. Courses of one to two weeks are usually adequate for soft-tissue infection, with longer treatment reserved for slowly resolving cases, and trials suggest that shorter courses are also feasible for osteomyelitis. Surgical source control and attention to perfusion remain essential companions to antimicrobial therapy.
References
- Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Clinical Infectious Diseases. 2023.
- Lipsky BA, Senneville É, Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes/Metabolism Research and Reviews. 2020.
- Matheson EM, Bragg SW, Blackwelder RS. Diabetes-related foot infections: diagnosis and treatment. American Family Physician. 2021;104(4).
- Maurer SM, Hepp ZS, McCallin S, et al. Short and oral antimicrobial therapy for diabetic foot infection: a narrative review of current knowledge. Journal of Bone and Joint Infection. 2022.
- Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care. 2015.
- Gariani K, Pham TT, Kressmann B, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial. Clinical Infectious Diseases. 2021.
Comments
